|
Ultrasound abnormalities
|
Arthritis, yes
|
Arthritis, no
|
OR (95% CI)d
|
p value
|
|---|
|
Clinical prediction rule risk-groupsa
|
n = 51
|
n = 112
|
|---|
|
Synovial thickeningb (16 joints)
| | |
1.5 (0.7–3.4)
|
0.3
|
|
Clinical prediction rule
| | |
3.5 (2.2–5.4)
|
< 0.01
|
|
Low risk
|
2/8 (25%)
|
19/67 (28%)
| | |
|
Intermediate risk
|
5/13 (38%)
|
5/25 (20%)
| | |
|
High risk
|
12/30 (40%)
|
6/20 (30%)
| | |
|
Synovial thickening (10 joints, no MTP)
| | |
6.1 (CI 1.6–23.2)
|
< 0.01
|
|
Clinical prediction rule
| | |
3.5 (CI 2.2–5.5)
|
< 0.01
|
|
Low risk
|
0/8 (0%)
|
3/67 (4%)
| | |
|
Intermediate risk
|
4/13 (31%)
|
1/25 (4%)
| | |
|
High risk
|
6/30 (20%)
|
0/20 (0%)
| | |
|
Power Dopplerb (16 joints)c
| | |
1.7 (0.3–10.2)
|
0.5
|
|
Clinical prediction rule
| | |
3.6 (2.3–5.6)
|
< 0.01
|
|
Low risk
|
0/8 (0%)
|
4/67 (6%)
| | |
|
Intermediate risk
|
2/13 (15%)
|
1/25 (4%)
| | |
|
High risk
|
0/30 (0%)
|
0/20 (0%)
| | |
- ACPA anti-citrullinated protein antibody, CI confidence interval, MTP metatarsophalangeal, OR odds ratio, RF rheumatoid factor
- aRisk groups based on the clinical prediction rule described in reference number 4
- bResults are presented for synovial thickening and power Doppler in at least one joint (present, %)
- cSame results when excluding MTP joints
- dLogistic regression analysis (note that the prediction rule risk groups were combined)
